Trump gets Pfizer to delay latest drug price hikes until year end

Pfizer has agreed to roll back a round of price increases from July 1 that affected more than 100 medicines after President Donald Trump called the company’s CEO and had an “extensive discussion,” the company announced Tuesday.

Now, Pfizer says it will return the drugs to their pre-July 1 list prices “as soon as technically possible,” and it will leave them there until either the President puts in place new healthcare policy or until the end of the year—whichever comes first.

The idea is to “give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access for patients,” Pfizer said in its announcement.

Read 7 remaining paragraphs | Comments

Leave a Reply

Read the original at Ars Technica.